Abstract:A major obstacle of the selective inhibitor design for specific human phosphodiesterase (PDE) is that highly conserved catalytic pockets are difficult to be distinguished by inhibitor molecules. To overcome this, a feasible path is to understand the molecular determinants underlying the selectivity of current inhibitors. BAY60-7550 (BAY for short; IC50 = 4.7 nM) is a highly selective inhibitor targeting PDE2A which is a dual-specificity PDE and an attractive target for therapeutic intervention of the central nervous system (CNS) disorders. Recent studies suggest that molecular determinants may be in binding processes of BAY. However, a detailed understanding of these processes are still lacking. To explore these processes, High-Throughput Molecular Dynamics (HTMD) simulations were performed to reproduce the spontaneous association of BAY with catalytic pockets of 4 PDE isoforms; Ligand Gaussian Accelerated Molecular Dynamics (LiGaMD) simulations were performed to reproduce the unbinding-rebinding processes of FKG and MC2, two pyrazolopyrimidinone PDE2A selective inhibitors, in the PDE2A system. The produced molecular trajectories were analyzed by the Markov state model (MSM) and the molecular mechanics/generalized Born surface area (MM/GBSA). The results showed that the non-covalent interactions between the non-conserved residues and BAY, especially the hydrogen bonds, determined the unique binding pathways of BAY on the surface of PDE2A. These pathways were different from those of BAY on the surface of the other three PDE isoforms and the binding pathways of the other two PDE2A inhibitors in PDE2A systems. These differences were ultimately reflected in the high selectivity of this inhibitor for PDE2A. As a result, this study demonstrates the critical role of the binding processes in the selectivity of BAY, and also identifies the key non-conserved residues affecting the binding processes of BAY. Thus, this study provides a new perspective and data support for the further development of BAY-derived inhibitors targeting PDE2A.

Distinctive Binding Modes and Inhibitory Mechanisms of Two Peptidic Inhibitors of Urokinase-Type Plasminogen Activator with Isomeric P1 Residues.

Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs.

The Binding Mechanism of A Peptidic Cyclic Serine Protease Inhibitor

Structural Basis of Specificity of a Peptidyl Urokinase Inhibitor, Upain-1

A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility

Structural Principles In The Development Of Cyclic Peptidic Enzyme Inhibitors

The Structure Basis of the Poor Fibrin Specificity of Urokinase (Ii)--the Inhibition of Urokinase A Chain 149-157 on the Fibrin Stimulated Activation of Plasminogen by Tissue Type Plasminogen Activator.

Insight to the Residue in P2 Position Prevents the Peptide Inhibitor from Being Hydrolyzed by Serine Proteases

Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action

Cleavage of Peptidic Inhibitors by Target Protease is Caused by Peptide Conformational Transition.

Crystal Structures of Urokinase-Type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol

Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres

Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1

Design of Specific Serine Protease Inhibitors Based on A Versatile Peptide Scaffold: Conversion of A Urokinase Inhibitor to A Plasma Kallikrein Inhibitor

Subtle Structural Differences Affect the Inhibitory Potency of RGD-Containing Cyclic Peptide Inhibitors Targeting SPSB Proteins

Probing nanosecond motions of plasminogen activator inhibitor-1 by time-resolved fluorescence anisotropy.

Long-Timescale Simulations Revealed Critical Non-Conserved Residues of Phosphodiesterases Affecting Selectivity of BAY60-7550

Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by A Small-Molecule Antagonist

High-throughput amino acid-level characterization of the interactions of plasminogen activator inhibitor-1 with variably divergent proteases

Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin

Small Molecules Engage Hot Spots Through Cooperative Binding to Inhibit a Tight Protein-Protein Interaction.